MPC-06ID is a Cell Therapy owned by Mesoblast, and is involved in 3 clinical trials, of which 2 were completed, and 1 is planned.
Mesoblast’s allogeneic adult stem cells when injected into severely damaged intervertebral discs results in dramatic reversal of the degenerative process, regrowth of disc cartilage and sustained normalization of disc pathology, anatomy and function. Since MPCs produce the proteoglycan materials found in discs, it is anticipated that the injection of MPCs into a degenerated intervertebral disc will lead to replacement of the proteoglycan of cartilage.
The revenue for MPC-06ID is expected to reach a total of $535m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the MPC-06ID NPV Report.
MPC-06ID is originated and owned by Mesoblast.
Mesenchymal precursor cells (MPC-06-ID) are under development for the treatment of chronic discogenic lower back pain (CDLBP) due to degenerative intervertebral disc disease. The therapeutic candidate is administered by percutaneous injection. The therapeutic candidate is based on mesenchymal precursor cell (MPC) technology platform.
Mesoblast is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.
The company reported revenues of (US Dollars) US$10.2 million for the fiscal year ended June 2022 (FY2022), an increase of 37% over FY2021. The operating loss of the company was US$74.1 million in FY2022, compared to an operating loss of US$85.2 million in FY2021. The net loss of the company was US$91.4 million in FY2022, compared to a net loss of US$98.8 million in FY2021.
Quick View – MPC-06ID
|Highest Development Stage|